The Jackson Laboratory completed acquisition of the New York Stem Cell Foundation to create an integrated research and translational platform, the institutions said. The deal combines JAX’s genetics and model organism strengths with NYSCF’s stem‑cell capabilities to accelerate discovery and precision therapy development. Executives framed the union as a strategic consolidation to speed translational pipelines, expand infrastructure for cell and iPSC work, and bolster partnerships with pharma and academic centers. The transaction aims to shorten the path from stem‑cell discovery to clinical testing and to strengthen preclinical platforms used by biotech partners.